Belgium · Biotechnology startup
Belgium · Ra Pharmaceuticals
Ra Pharma is developing Cyclomimetics, a new drug class combining the properties and benefits of antibodies and small molecules.
Funding reportedLast round: Post ipo equity
What company datasets say Ra Pharmaceuticals raised
Funding, as reported
Reported in all226.9Min the source's currency
Rounds4
Last roundPost ipo equity
Last round dateJul 2019
Investors listed9
Founders and team
From Ra Pharmaceuticals's own website: 10 on the team.
- Alistair HenryExecutive Vice President
- Emmanuel CaeymaexExecutive Vice President
- Fiona du MonceauExecutive Vice President
- Jacques MarbehantExecutive Vice President
- Patient EvidenceExecutive Vice President
- Patient SupplyExecutive Vice President
- Sandrine DufourExecutive Vice President
- Denelle Waynick JohnsonTeam
- Jean-Christophe TellierTeam
- Jean-Luc FleurialTeam
On a portfolio page
Investors who name them
Each firm lists Ra Pharmaceuticals on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
Biotechnology in Belgium
Startups like it
Is this your company?
Add your raise, your deck and your story, and put Ra Pharmaceuticals in front of investors. Or tell us what we have wrong.